

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3226890/publications.pdf Version: 2024-02-01



STEDN CAL

#	Article	IF	CITATIONS
1	Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments. Neuropharmacology, 2022, 205, 108913.	2.0	13
2	Female but not male rats show biphasic effects of low doses of Δ9-tetrahydrocannabinol on anxiety: can cannabidiol interfere with these effects?. Neuropharmacology, 2021, 196, 108684.	2.0	16
3	A timeâ€dependent contribution of hippocampal CB ₁ , CB ₂ and PPARγ receptors to cannabidiolâ€induced disruption of fear memory consolidation. British Journal of Pharmacology, 2020, 177, 945-957.	2.7	29
4	Effects of â^†9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies. BMC Psychiatry, 2020, 20, 420.	1.1	23
5	The role of prelimbic and anterior cingulate cortices in fear memory reconsolidation and persistence depends on the memory age. Learning and Memory, 2020, 27, 292-300.	0.5	12
6	Persistence of the extinction of fear memory requires late-phase cAMP/PKA signaling in the infralimbic cortex. Neurobiology of Learning and Memory, 2020, 172, 107244.	1.0	14
7	Role of prelimbic cortex PKC and PKMζ in fear memory reconsolidation and persistence following reactivation. Scientific Reports, 2020, 10, 4076.	1.6	18
8	Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes. Neuroscience Letters, 2020, 729, 135020.	1.0	16
9	Posttraumatic stress disorder-type behaviors in streptozotocin-induced diabetic rats can be prevented by prolonged treatment with vitamin E. Behavioural Brain Research, 2019, 359, 749-754.	1.2	15
10	Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies. Psychopharmacology, 2019, 236, 201-226.	1.5	42
11	Effects of ketamine on vocal impairment, gait changes, and anhedonia induced by bilateral 6-OHDA infusion into the substantia nigra pars compacta in rats: Therapeutic implications for Parkinson's disease. Behavioural Brain Research, 2018, 342, 1-10.	1.2	19
12	Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation. Neuroscience, 2018, 370, 62-80.	1.1	39
13	Newly acquired and reactivated contextual fear memories are more intense and prone to generalize after activation of prelimbic cortex NMDA receptors. Neurobiology of Learning and Memory, 2017, 137, 154-162.	1.0	28
14	Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors. Neuropharmacology, 2017, 125, 220-230.	2.0	69
15	Evidence for an expanded time-window to mitigate a reactivated fear memory by tamoxifen. European Neuropsychopharmacology, 2016, 26, 1601-1609.	0.3	16
16	Efficacy and security of ivermectin given orally to rats naturally infected with <i>Syphacia</i> spp., <i>Giardia</i> spp. and <i>Hymenolepis nana</i> . Laboratory Animals, 2015, 49, 196-200.	0.5	11
17	PTSD-Like Memory Generated Through Enhanced Noradrenergic Activity is Mitigated by a Dual Step Pharmacological Intervention Targeting its Reconsolidation. International Journal of Neuropsychopharmacology, 2015, 18, pyu026-pyu026.	1.0	67
18	Δ-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. European Neuropsychopharmacology, 2015, 25, 958-965.	0.3	62

Stern CAJ

#	Article	IF	CITATIONS
19	Activity in prelimbic cortex subserves fear memory reconsolidation over time. Learning and Memory, 2014, 21, 14-20.	0.5	44
20	Enhanced noradrenergic activity potentiates fear memory consolidation and reconsolidation by differentially recruiting $\hat{l}\pm 1$ - and \hat{l}^2 -adrenergic receptors. Learning and Memory, 2013, 20, 210-219.	0.5	93
21	On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment. Neuropsychopharmacology, 2012, 37, 2132-2142.	2.8	136
22	Protein synthesis in dorsal hippocampus supports the drug tolerance induced by prior elevated plus-maze experience. Neuroscience, 2011, 179, 179-187.	1.1	6
23	Activity in prelimbic cortex is required for adjusting the anxiety response level during the elevated plus-maze retest. Neuroscience, 2010, 170, 214-222.	1.1	57
24	Aversive learning as a mechanism for lack of repeated anxiolytic-like effect in the elevated plus-maze. Pharmacology Biochemistry and Behavior, 2008, 90, 545-550.	1.3	29
25	Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behavioural Pharmacology, 2008, 19, 357-360.	0.8	51